Daily Stock Analysis, BMRN, Biomarin Pharmaceutical Inc, priceseries

Biomarin Pharmaceutical Inc. Daily Stock Analysis
Stock Information
Open
79.53
Close
78.77
High
79.80
Low
78.42
Previous Close
79.43
Daily Price Gain
-0.66
YTD High
100.13
YTD High Date
Feb 5, 2019
YTD Low
62.88
YTD Low Date
Oct 2, 2019
YTD Price Change
-6.19
YTD Gain
-7.29%
52 Week High
100.13
52 Week High Date
Feb 5, 2019
52 Week Low
62.88
52 Week Low Date
Oct 2, 2019
52 Week Price Change
-15.74
52 Week Gain
-16.65%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 30. 2017
87.65
Sep 27. 2017
92.87
19 Trading Days
5.96%
Link
LONG
Jul 5. 2018
95.50
Jul 23. 2018
101.66
12 Trading Days
6.45%
Link
LONG
Jan 4. 2019
87.10
Jan 23. 2019
92.95
12 Trading Days
6.72%
Link
LONG
Oct 23. 2019
69.01
Nov 15. 2019
75.06
17 Trading Days
8.76%
Link
Company Information
Stock Symbol
BMRN
Exchange
NasdaqGS
Company URL
http://www.biomarin.com
Company Phone
4155066700
CEO
Jean-Jacques Bienaimé
Headquarters
California
Business Address
105 DIGITAL DRIVE, NOVATO, CA 94949
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001048477
About

BioMarin Pharmaceutical, Inc. engages in the biopharmaceutical development and commercialization of innovative pharmaceuticals for serious diseases and medical conditions. Its company's products include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM. The company was founded on March 21, 1997 and is headquartered in Novato, CA.

Description

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.